»ÆÐ۸ߣ¬Ö÷ÈÎҽʦ£¬²©Ê¿Éúµ¼Ê¦£¬¼±¾ÈÓë´´ÉËÑо¿½ÌÓý²¿ÖصãʵÑ鸱Ö÷ÈΣ¬¸£ÀûÌìÌõÚÒ»¸½ÊôÒ½Ôº¸±Ôº³¤£¨µÚÒ»ÁÙ´²Ò½Ñ§Ôº³£Îñ¸±Ôº³¤£©£¬ÑÛ¿Æ¿ÆÖ÷ÈΣ¬ÑÛ¿Æѧ½ÌÑÐÊÒÖ÷ÈΣ¬ÑÛ¿Æѧ¿Æ´øÍ·ÈË¡£º£ÄÏʡҽѧ»áÑÛ¿Æѧ·Ö»áÖ÷ÈÎίԱ£¬Ñ۵ײ¡ÑÛÍâÉËѧ×é×鳤¡¢¡¶ÖлªÑÛÍâÉËÖ°ÒµÑÛ²¡ÔÓÖ¾¡·±àί¡£Î人´óѧÑÛ¿Æѧҽѧ˶ʿ£¬ÖÐɽ´óѧÖÐɽÑÛ¿ÆÖÐÐÄҽѧ²©Ê¿£¬ÃÀ¹ú¹þ·ð´óѧSchepens ÑÛ¿ÆÑо¿Ëù²©Ê¿ºó£¬³¤ÆÚÖÂÁ¦ÓÚÑÛµ×ÐÂÉúѪ¹ÜÐÔ¼²²¡¼°ÔöÉúÐÔ²£Á§ÌåÊÓÍøĤ²¡±ä·¢²¡»úÖƼ°ÁÙ´²·ÀÖεÄÑо¿£¬ÔÚ¡¶Nature Communications¡·¡¶Journal of advanced research¡·¡¶Invest Ophthalmol Vis Sci¡·¡¶Clinical experimental ophthalmology¡·¡¶Experimental eye research¡·µÈ×ۺϼ°ÑÛ¿ÆרҵÔÓÖ¾·¢±íÂÛÎÄ26ƪÂÛÎÄ¡£
ÓÊÏ䣺hxg_eye@163.com
